Time Trends of Crohn’s Disease in Catalonia from 2011 to 2017. Increasing Use of Biologics Correlates with a Reduced Need for Surgery
| Autor: | Pilar García-Iglesias, Xavier Calvet, Caridad Pontes, L Melcarne, Eduard Brunet, Mercedes Vergara, Marta Gallach, Albert Villoria, Montserrat Cleries, Emili Vela, Laura Patricia Llovet |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Drug
Crohn’s disease medicine.medical_specialty Epidemiology media_common.quotation_subject Population lcsh:Medicine Disease Inflammatory bowel disease Article 03 medical and health sciences 0302 clinical medicine inflammatory bowel disease medicine 030212 general & internal medicine education media_common education.field_of_study Crohn's disease business.industry Time trends lcsh:R General Medicine medicine.disease digestive system diseases Surgery Clinical trial 030211 gastroenterology & hepatology epidemiology business |
| Zdroj: | Journal of Clinical Medicine Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Volume 9 Issue 9 Journal of Clinical Medicine, Vol 9, Iss 2896, p 2896 (2020) |
| ISSN: | 2077-0383 |
| Popis: | Background and Aims: Data from clinical trials suggest that biological drugs may improve the outcomes in Crohn&rsquo s disease (CD) by reducing the need for surgery or hospitalization. The aim of this study is to evaluate the time-trends of the use of biological drugs and other treatments for CD, and its relationship with outcomes in Catalonia. Materials and Methods: All patients with CD included in the Catalan Health Surveillance System (containing data on a population of more than 7.5 million) from 2011 to 2017 were identified. The exposures to different treatments for inflammatory bowel disease were retrieved from electronic invoicing records. Results: Between 2011 and 2017, the use of salicylates, corticosteroids and immunosuppressive treatment fell from 28.8% to 17.1%, 15.8% to 13.7%, and 32.9% to 29.6%, respectively (p < 0.001). Biological treatment use rose from 15.0% to 18.7% (p < 0.001). Ostomy rates per 1000 patients/year fell from 13.2 in 2011 to 9.8 in 2017 (p = 0.003), and surgical resection rates from 24.1 to 18.0 (p < 0.001). The rate of CD-related hospitalizations per 1000 patients/year also fell, from 92.7 to 72.2 (p < 0.001). Conclusions: Biological drug use rose from 15.0% to 18.7% between 2011 and 2017. During this period, we observed an improvement in the outcomes of CD patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|